|Bid||139.29 x 800|
|Ask||139.60 x 1100|
|Day's Range||133.51 - 139.65|
|52 Week Range||117.91 - 213.94|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||38.84|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Speakers on today's call will be Clay Siegall, president and chief executive officer; Chip Romp, executive vice president, commercial U.S.; Todd Simpson, chief financial officer; and Roger Dansey, chief medical officer. Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2021 financial outlook, anticipated product sales, revenues, costs and expenses, and potential clinical and regulatory milestones, including data readouts, regulatory submissions, and approvals. Factors that may cause such a difference include the difficulty in forecasting sales, revenues, and expenses, impacts related to the COVID-19 pandemic, and the uncertainty associated with the pharmaceutical development and regulatory approval process.
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.56% and -2.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2021.